Archive

ASCO Highlights

Written by Karen Ramirez | 20 Aug 2018

June 2018 saw the launch of our first edition of LungCancer.Med, a new congress news e-journal containing interviews with speakers and delegates as well as articles on the latest hot… read more.

EHA 2018: Immunotherapy in MM: why, when and how?

Written by Karen Ramirez | 24 Jun 2018

The pathophysiology of MM is characterised by a state of profound immunosuppression through multiple mechanisms which provides a strong rationale for immunotherapeutic approaches including antibodies, immunomodulators, vaccines and… read more.

EHA 2018: Preferred treatment combinations and sequencing in transplant eligible and elderly MM patients

Written by Karen Ramirez | 24 Jun 2018

The growing number of novel treatments for multiple myeloma (MM) means that more patients can achieve the therapeutic goal of a deep and prolonged first remission – in… read more.

BSH 2018: Hodgkin lymphoma: tackling treatment challenges in the older patient

Written by Christine Clark | 21 Jun 2018

Managing Hodgkin lymphoma in elderly patients can be challenging, given that trial data do not reflect the picture in elderly patients and performance status can vary widely. The… read more.

BSH 2018: Molecular biology to drive rational drug usage

Written by Christine Clark | 20 Jun 2018

Gene expression profiling has shown that that the activated B-cell and germinal centre B-cell subtypes of diffuse large B-cell lymphoma are driven by different oncogenic pathways and this may… read more.

BSH 2018 Highlights

Written by Karen Ramirez | 20 Jun 2018

In the video, Dr Cathy Burton (Leeds), Dr Stella Bowcock (London) and Dr Stephen Robinson (Bristol) give their highlights from this year’s BSH meeting, including the Lymphoma Specialist Interest Group (SIG) which held a… read more.

BSH 2018: Creating off-site, nurse-led treatment units for administration of chemotherapy to people with lymphoma

Written by Christine Clark | 20 Jun 2018

The launch of biosimilar rituximab provided an opportunity to save £300,000 per year but called for time-consuming intravenous administration that exceeded the capacity of the hospital unit. Off-site… read more.

Real-world data shows details beyond the clinical trials

Written by Karen Ramirez | 21 Feb 2018

Professor Paul G. Richardson MD (R.J. Corman Professor, Medicine, Harvard Medical School, Boston, USA) and Dr Karthik Ramasamy (Oxford Oncology and Haematology Centre) discuss important learnings from real-world… read more.

ECCO 2018: Novel treatments in IBD

Written by Karen Ramirez | 11 Feb 2018

The current research and development pipeline of novel biologic therapies and small molecule drugs promises improved efficacy and safety in the treatment of IBD in the near future…. read more.

ASH 2017: Mixed results for new NHL therapies

Written by Alex Burton | 19 Jan 2018

Article written by Tom Collins. Interviews by Esther Drain. Trying to usher new immunotherapies into the setting of non-Hodgkin lymphomas (NHL) has been met with mixed results, and… read more.

ASH 2017: ECHELON-1: Brentuximab vedotin plus AVD in HL produces PFS improvement

Written by Alex Burton | 19 Jan 2018

Article written by Tom Collins. Interviews by Esther Drain. Replacing bleomycin with brentuximab vedotin (A+AVD) in the traditional regimen for previously untreated Hodgkin lymphoma patients significantly improved modified… read more.

ASH 2017: Experts offer guidance on smouldering myeloma

Written by Alex Burton | 17 Jan 2018

Article written by Tom Collins. Interview by Esther Drain. Even as definitions of risk groups in myeloma become more sophisticated, a reasonable way to assess those patients with… read more.

« Previous 1 … 23 24 25 26 27 … 37 Next »

Archive

Subscribe for our mailing list

Follow Us